Skip to main content
Welcome to
super saver spring
offer ends april 20
save over $140
save over 85%
$0.99
per week for 24 weeks
Welcome to
super saver spring
$0.99
per week
for 24 weeks
// //

Prime Minister Justin Trudeau cautioned Canadians that a successful COVID-19 vaccine likely won’t be ready this year or even early in the new year as he announced an additional $214-million in spending on Canadian-made vaccines Friday.

“We are hopeful the vaccines will arrive yesterday, but they won’t. There’s still a number of more months of work to do,” Mr. Trudeau told reporters. “I think that reasonable expectations is that vaccines could start to arrive some time in the new year, but even then, there will be smaller amounts of doses that will have to be distributed to priority populations.”

Mr. Trudeau said vulnerable populations and front-line workers will be given priority access to the vaccines once they are ready.

Story continues below advertisement

“We have experts busy evaluating exactly how and where and in which way to distribute these vaccines. We will of course be working closely with provinces and territories to ensure that it’s done the right way,” he said.

COVID-19 news: Updates and essential resources about the pandemic

Is my city going back into lockdown? A guide to COVID-19 rules across Canada

Friday’s funding announcement included up to $173-million for the Quebec biopharmaceutical company Medicago Inc., including support to create a production facility in Quebec City. The Quebec company has also reached an agreement with Ottawa to supply up to 76 million doses of its vaccine, should it be approved for use.

"This is about securing potential vaccines for Canadians, while supporting good jobs in research,” Mr. Trudeau said.

Mr. Trudeau announced the funding at a news conference on Parliament Hill.

The Prime Minister also announced that Precision NanoSystems, a Vancouver-based biotech company, will receive up to $18.2-million for development and testing of a vaccine candidate. The government also announced over $23-million in funding for “earlier-stage” vaccine candidates being developed across the country.

“Canada has direct agreements with a range of vaccine developers for their most promising candidates,” Mr. Trudeau said. “When a vaccine is ready, Canada will be too.”

The federal government has previously announced agreements with several companies to secure access to their COVID-19 vaccines should they prove successful and receive approval for use in Canada. These companies include AstraZeneca, Sanofi and GlaxoSmithKline, Johnson & Johnson, Novavax, Pfizer and Moderna.

Story continues below advertisement

In a news release, the federal government said full payments to drug companies are contingent on the vaccines passing clinical trials and obtaining regulatory approval. All contracts the government signs with vaccine developers “contain off-ramps and exit provisions,” the government said.

World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus said earlier this month that there is hope that “by the end of this year, we may have a vaccine.”

Chief public health officer Dr. Theresa Tam says combating fake news about the COVID-19 pandemic is a serious challenge for public health. Tam and Prime Minister Justin Trudeau both say the amount of disinformation hitting Canadians about the pandemic is troubling. The Canadian Press

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies